| Primary |
| Pneumonia |
18.4% |
| Febrile Neutropenia |
15.8% |
| Infection |
9.0% |
| Osteomyelitis |
7.9% |
| Sepsis |
7.9% |
| Urinary Tract Infection |
6.2% |
| Pyrexia |
5.4% |
| Drug Use For Unknown Indication |
3.4% |
| Acute Myeloid Leukaemia |
2.8% |
| Product Used For Unknown Indication |
2.8% |
| Pseudomonas Infection |
2.8% |
| Respiratory Tract Infection |
2.5% |
| Escherichia Bacteraemia |
2.3% |
| Wound Infection |
2.3% |
| Abdominal Infection |
2.0% |
| Multiple Myeloma |
2.0% |
| Prophylaxis |
2.0% |
| Arthritis Bacterial |
1.7% |
| Bronchitis |
1.4% |
| Device Related Infection |
1.4% |
|
| Status Epilepticus |
18.4% |
| Rash |
11.7% |
| Myoclonus |
6.1% |
| Renal Failure Acute |
5.6% |
| Sepsis |
5.6% |
| Convulsion |
5.0% |
| White Blood Cell Count Decreased |
5.0% |
| Confusional State |
4.5% |
| Encephalopathy |
4.5% |
| Neurotoxicity |
4.5% |
| Overdose |
4.5% |
| Pyrexia |
3.9% |
| Thrombocytopenia |
3.9% |
| Toxicity To Various Agents |
3.4% |
| Treatment Failure |
2.8% |
| Urticaria |
2.8% |
| Acute Generalised Exanthematous Pustulosis |
2.2% |
| Neutropenia |
2.2% |
| Delirium |
1.7% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
22.8% |
| Drug Use For Unknown Indication |
20.3% |
| Febrile Neutropenia |
6.6% |
| Sepsis |
5.7% |
| Pneumonia |
5.0% |
| Multiple Myeloma |
4.3% |
| Prophylaxis |
4.3% |
| Acute Myeloid Leukaemia |
3.8% |
| Infection |
3.8% |
| Acute Lymphocytic Leukaemia |
3.2% |
| Bronchopulmonary Aspergillosis |
2.8% |
| Urinary Tract Infection |
2.5% |
| Cellulitis |
2.4% |
| Antibiotic Therapy |
2.3% |
| Hypertension |
1.8% |
| Impaired Healing |
1.7% |
| Pyrexia |
1.7% |
| Osteomyelitis |
1.7% |
| Abdominal Infection |
1.6% |
| Infection Prophylaxis |
1.6% |
|
| Status Epilepticus |
16.4% |
| Thrombocytopenia |
8.9% |
| Renal Failure Acute |
7.5% |
| Toxic Epidermal Necrolysis |
6.2% |
| Vomiting |
6.2% |
| Acute Generalised Exanthematous Pustulosis |
4.8% |
| Neutropenia |
4.8% |
| Rash |
4.8% |
| Renal Impairment |
4.8% |
| Tubulointerstitial Nephritis |
4.8% |
| Sepsis |
4.1% |
| Drug Ineffective |
3.4% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.4% |
| Septic Shock |
3.4% |
| Leukopenia |
2.7% |
| Pneumonia |
2.7% |
| Renal Failure |
2.7% |
| Streptococcal Infection |
2.7% |
| Unresponsive To Stimuli |
2.7% |
| Urinary Tract Infection |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
40.5% |
| Drug Use For Unknown Indication |
26.0% |
| Prophylaxis |
4.7% |
| Acute Myeloid Leukaemia |
2.8% |
| Acute Lymphocytic Leukaemia |
2.7% |
| Pain |
2.2% |
| Hypertension |
2.1% |
| Adverse Event |
1.9% |
| Multiple Myeloma |
1.8% |
| Pneumonia |
1.8% |
| Pyrexia |
1.7% |
| Nausea |
1.7% |
| Febrile Neutropenia |
1.7% |
| Diffuse Large B-cell Lymphoma |
1.6% |
| Infection Prophylaxis |
1.5% |
| Infection |
1.4% |
| Constipation |
1.4% |
| Premedication |
1.0% |
| Sepsis |
0.9% |
| Diabetes Mellitus |
0.8% |
|
| Vomiting |
11.9% |
| Sepsis |
10.5% |
| White Blood Cell Count Decreased |
8.6% |
| Weight Decreased |
6.1% |
| Thrombocytopenia |
5.7% |
| Pyrexia |
5.3% |
| Respiratory Failure |
5.3% |
| Septic Shock |
5.1% |
| Renal Failure Acute |
4.8% |
| Tachycardia |
4.8% |
| Pneumonia |
4.3% |
| Toxic Epidermal Necrolysis |
4.1% |
| Staphylococcal Infection |
3.8% |
| Unresponsive To Stimuli |
3.0% |
| Platelet Count Decreased |
2.9% |
| Rash |
2.9% |
| Weight Increased |
2.9% |
| White Blood Cell Count Increased |
2.9% |
| Febrile Neutropenia |
2.7% |
| International Normalised Ratio Increased |
2.5% |
|
| Interacting |
| Anaemia |
33.3% |
| Febrile Neutropenia |
33.3% |
| Thrombocytopenia |
33.3% |
|
| Pneumonia Klebsiella |
75.0% |
| Drug Interaction |
25.0% |
|
